Related Experiment Video

Updated: Jan 21, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Pharmacology of Ivabradine and the Effect on Chronic Heart Failure

Yue Zhou1, Jian Wang1, Zhuo Meng2

  • 1Department of Pediatric Cardiology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.

Current Topics in Medicinal Chemistry
|August 11, 2019
PubMed

Insights

Ivabradine effectively lowers heart rate (HR) by inhibiting the funny current (If) in heart failure patients. Clinical trials show it improves symptoms with minimal side effects, offering a new therapeutic option.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic Heart Failure (CHF) presents a significant global health challenge with suboptimal prognoses despite existing therapies.
  • Effective management of elevated Heart Rate (HR) is crucial for improving outcomes in CHF patients.

Purpose of the Study:

  • To review the pharmacological characteristics and mechanism of action of ivabradine, a novel bradycardic agent.
  • To explore the therapeutic potential of ivabradine in treating Chronic Heart Failure (CHF) and other conditions.

Main Methods:

  • Review of existing literature on ivabradine's chemical and pharmacological properties.
  • Analysis of clinical trial data demonstrating ivabradine's efficacy and safety in CHF.

Main Results:

  • Ivabradine inhibits the funny current (If) by binding to Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels, reducing HR.
  • Clinical studies confirm ivabradine's significant HR reduction and symptom improvement in CHF patients with a favorable safety profile.

Conclusions:

  • Ivabradine represents a promising therapeutic agent for managing CHF by targeting HR.
  • Further research is warranted to fully elucidate the pharmacological functions of ivabradine as an If channel inhibitor.

Keywords:
Chronic heart failureFunny currentHeart rateHyperpolarization-activated cyclic nucleotide- gatedIf channel inhibitorIvabradinePharmacology.

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225